Stock Ratings | Canaccord Genuity: Maintains a "Buy" rating on Zevra Therapeutics (ZVRA), raises price target to $25, expects 214.86% upside.
Zevra Therapeutics, Inc. ZVRA | 0.00 | |
E. W. Scripps Company Class A SSP | 0.00 | |
Cybin CYBN | 0.00 | |
Inozyme Pharma INZY | 0.00 | |
CervoMed Inc. CRVO | 0.00 |
Major US investment bank ratings are used to track the latest valuations and target prices on Wall Street daily, and to explore potential stock investment opportunities.
Today's Key Ratings and Concerns
Canaccord Genuity: Maintained a "Buy" rating on Zevra Therapeutics Inc Ordinary Shares(ZVRA.US) ), raising the price target from $23 to $25.
Benchmark: Maintained a "Buy" rating on E. W. Scripps Company Class A(SSP.US) ), raising the price target from $7 to $8.
Guggenheim: Maintained a "Buy" rating on Zevra Therapeutics Inc Ordinary Shares(ZVRA.US) ), raising the price target from $20 to $22.
Guggenheim: Initial rating for Cybin Inc. Common Shares Cybin Inc. Common Shares(CYBN.US) with a "Buy" recommendation and a $35 price target.
Raymond James: Maintained an "Outperform" rating on Inozyme Pharma(INZY.US) ), lowering the price target from $24 to $12.
| Investment objective | The symbol | Classification | Target price | Current price | Potential increase/decrease rate | (Classification) Agency |
| Zevra Therapeutics Inc Ordinary Shares | Zevra Therapeutics Inc Ordinary Shares(ZVRA.US) | to lift | $25.0 | $7.94 | 214.86% | Canaccord Genuity |
| EW Scripps Company Class A | E. W. Scripps Company Class A(SSP.US) | to lift | $8.0 | $2.73 | 193.04% | Benchmark |
| Zevra Therapeutics Inc Ordinary Shares | Zevra Therapeutics Inc Ordinary Shares(ZVRA.US) | to lift | $22.0 | $7.94 | 177.08% | Guggenheim |
| CervoMed Inc. - Common Stock | CervoMed Inc. - Common Stock(CRVO.US) | to lift | $15.0 | $5.79 | 159.07% | Jones Trading |
| CervoMed Inc. - Common Stock | CervoMed Inc. - Common Stock(CRVO.US) | to lift | $14.0 | $5.79 | 141.8% | Chardan Capital |
| Cybin Inc. Common Shares | Cybin Inc. Common Shares(CYBN.US) | Initial classification | $35.0 | $7.3 | 379.45% | Guggenheim |
| Inozyme Pharma | Inozyme Pharma(INZY.US) | cut | $12.0 | $0.9997 | 1100.36% | Raymond James |
| TENAYA THERAPEUTICS, INC. | TENAYA THERAPEUTICS, INC.(TNYA.US) | cut | $6.0 | $0.6702 | 795.26% | Canaccord Genuity |
| Q32 Bio Inc. - Common Stock | Q32 Bio Inc. - Common Stock(QTTB.US) | cut | $15.0 | $1.84 | 715.22% | Wells Fargo |
| Solo Brands, Inc. | Solo Brands, Inc.(DTC.US) | cut | $1.0 | $0.22 | 354.55% | Canaccord Genuity |
comments:
Target price unit and current price: US dollar;
Current Price: As of the latest closing price of US stocks;
Potential increase/decrease ratio = (Agency target price - current price) / current price 100% (Current price = last closing price up to the time of census)
Lifting
RBC Capital: Maintained Albertsons Companies, Inc.(ACI.US) ) “Outperform” rating, raising price target from $22 to $23.
BMO Capital: Maintained American American International Group, Inc.(AIG.US) “Market Match” rating, raising price target from $75 to $83.
Stephens & Co.: Raised Alkami Technology ( ALKAMI TECHNOLOGY, INC.(ALKT.US) ) to "Overweight", with a $40 price target.
JP Morgan: Maintained an “Overweight” rating on Antero Resources ( Antero Resources Corporation(AR.US) ), raising the price target from $45 to $47.
HC Wainwright & Co.: Maintained a "Buy" rating on Avino Silver Avino Silver & Gold Mines Ltd.(ASM.US) ), raising the price target from $1.9 to $2.2.
First coverage
RBC Capital: Initial rating for Alkermes Plc(ALKS.US) ) at "Sector Match", with a $40 price target.
Citigroup: Initial rating for Apogee Therapeutics(APGE.US) ) with a "Buy" recommendation and a $95 price target.
Truist Securities: Initial rating for ArcBest ( ArcBest Corporation(ARCB.US) ) with a "Buy" recommendation and a $93 price target.
reduction
UBS: Maintains a "Neutral" rating on ABM Indus ( ABM Industries Incorporated(ABM.US) ), lowers the price target from $56 to $50.
BMO Capital: Maintain Adobe ( Adobe Systems Incorporated(ADBE.US) ) "Outperform" rating, lower price target from $515 to $495.
Stifel: Maintained a "Buy" rating on Adobe ( Adobe Systems Incorporated(ADBE.US) ), lowering the price target from $600 to $525.
JP Morgan: Maintains a "Neutral" rating on APA ( Apache Corporation(APA.US) ), lowers the price target from $23 to $20.
Wells Fargo: Maintained an "overweight" rating on Arvinas ( Arvinas(ARVN.US) ), lowering the price target from $60 to $26.
Editor's Note: This content was generated by Sahm's AI-powered SaaS tool and reviewed by our editorial team.
Hazard Warning:
Investing involves risks, and securities prices may rise, fall, or even become worthless. Investing does not guarantee profits and may result in losses. Past performance does not necessarily reflect future performance. Before making any investment decision, investors should evaluate their financial situation, investment objectives, experience, and risk tolerance, and understand the nature of the investment products and the risks associated with them. For further details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, you are advised to seek independent professional advice.